Clinical trials: Kidney Transplant Recipient
EBV Viremia, CMV Viremia
Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
The aim of our study is to reduce viral (CMV and EBV) transmission from donor to recipient. The discovery that anti-retroviral therapy to mothers with HIV reduced transmission of the virus to their babies was pivotal to the…
- Trial name
- NCT01329185
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Minnesota
Chronic Kidney Failure, Graft vs Host Disease
Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients
The incidence of efficacy failure at 12 months between two regimens.
- Conditions
- Chronic Kidney Failure, Graft vs Host Disease, Kidney Transplantation
- Trial name
- NCT00044720
- Testing
- Rapamune
- Volunteers
- 484 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Cancer
Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
RATIONALE: Giving itraconazole or fluconazole may be effective in preventing infections in patients undergoing peripheral stem cell or bone marrow transplantation.
- Trial name
- NCT00003883
- Testing
- fluconazole, itraconazole
- Where
- 2 sites in United States
- Volunteers
- 578 people
- Sponsor
- Fred Hutchinson Cancer Center
Kidney Transplant, Urinary Tract Infection(UTI)
Antibiotics for Kidney Transplant Recipients
The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant.
- Conditions
- Kidney Transplant, Urinary Tract Infection(UTI), Antibiotic Prophylaxis, Remote Patient Monitoring
- Trial name
- TASK (NCT07106125)
- Testing
- Trimethoprim-Sulfamethoxazole (TMP-SMX), Usual Care
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Recurrent Glomerular Disease After Kidney Transplantation
A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients
To assess the efficacy and safety of pegcetacoplan for the prevention of recurrent C3G or primary IC-MPGN in kidney transplant recipients
- Trial name
- PRESERVE (NCT07898774)
- Testing
- Pegcetacoplan
- Where
- 33 sites in Brazil, Canada and 8 more
- Volunteers
- 30 people
- Sponsor
- Swedish Orphan Biovitrum
End-Stage Renal Disease, End Stage Renal Disease on Dialysis
CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk
This clinical trial investigates the transplantation of donor kidneys that have been genetically modified ex vivo using CRISPR-Cas9 genome editing to reduce immunogenicity and transplant rejection.
- Conditions
- End-Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Renal Disease With Renal Transplant, Kidney Transplant Rejection
- Trial name
- NCT07053462
- Testing
- Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney, Kidney Transplantation with Standard Care
- Where
- China
- Volunteers
- 90 people
- Sponsor
- AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Kideny Transplant Recipients With High Cardiovascular Risk Score
PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients
From this randomized controlled study, we aim to: A.Do do cardiovascular risk stratification of renal transplant recipients who are followed up in Hamed Al-Essa organ transplant center of Kuwait. B.
- Trial name
- NCT04665830
- Testing
- Evolocumab
- Where
- Kuwait
- Volunteers
- 200 people
- Sponsor
- Hamid Al-Essa Organ Transplant Center
Kidney Transplant Recipient
Isoniazid (INH) Treatment Based on ELISPOT Assay
It has been recommended that all transplant recipients undergo a tuberculin skin test (TST) before transplantation. However, the ability of TST to diagnose latent tuberculosis infection (LTBI) in transplant candidates has been…
- Trial name
- NCT01087190
- Testing
- Isoniazid treatment
- Where
- South Korea
- Volunteers
- 831 people
- Sponsor
- Asan Medical Center
Kidney Transplantation
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
This study compared the incidence of a two-part composite endpoint consisting of de novo donor specific antibody (DSA) formation or a designation of immune activation (IA) on peripheral blood molecular profiling in participants…
- Trial name
- ASTOUND (NCT02723591)
- Testing
- Tacrolimus, Tacrolimus immediate release
- Where
- 30 sites in United States
- Volunteers
- 599 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Kidney Transplant
Optimization of Therapeutic Drug Monitoring in Pediatric Kidney Transplant
The goal of this observational, pharmacokinetic study is to evaluate factors that change drug exposure in pediatric kidney transplant recipients so investigators can make better dosing decisions.
- Trial name
- NCT07769567
- Volunteers
- 25 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Kidney Diseases
Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients
The purpose of this study is to evaluate the effectiveness of nutritional supplements in increasing the amount of omega-3 fatty acids (and arginine) in the red blood cell membranes and plasma of kidney transplant patients, and…
- Trial name
- NCT00047983
- Testing
- Canola oil, Arginine, Fish oil emulsion
- Where
- 4 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
De Novo Renal Transplant Recipient.
Fixed Dose MMF vs Concentration Controlled MMF After Renal Transplantation
Determine the value of a clinically feasible strategy of therapeutic drug monitoring compared with fixed dosing in de novo MMF treated renal transplant recipients with respect to the incidence of treatment failure.
- Trial name
- NCT00166244
- Testing
- Mycophenolate Mofetil
- Where
- 67 sites in Australia, Austria and 17 more
- Volunteers
- 901 people
- Sponsor
- Erasmus Medical Center
EBV Infection, EBV Viremia
EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients
Transplant recipients are treated with immunosuppressive drugs to avoid rejection of the transplanted organ. As the medication impairs the immune response, it also increases the risk of serious infections and cancer in transplant…
- Conditions
- EBV Infection, EBV Viremia, Epstein-Barr Virus Associated Lymphoproliferative Disorder, Post-transplant Lymphoproliferative Disorder
- Trial name
- EVITA (NCT04189835)
- Testing
- EBV DNA in whole blood and plasma
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 509 people
- Sponsor
- University of Aarhus
Renal Transplantation; Complication
Hypomagnesemia and Its Association With Calcineurin Inhibitors Use in Renal Transplant Recipients
To assess the prevalence and risk factors of hypomagnesemia and its association with calcineurin inhibitor use among Egyptian renal transplant recipients.
- Trial name
- NCT05352880
- Testing
- serum magnesium level, FEMg
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Alexandria University
Kidney Failure, Chronic, Kidney Transplantation
Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients
The purpose of this study is to evaluate the safety of alemtuzumab after kidney transplantation as part of a multitherapy regimen to prevent kidney graft loss and death and to avoid steroids and chronic use of calcineurin…
- Conditions
- Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression
- Trial name
- NCT00240994
- Testing
- Alemtuzumab, Tacrolimus, Mycophenolate mofetil
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplantation, Pediatric Patients
Conversion of Prograf to Advagraf in Pediatric Renal Transplant Recipients
This study was designed to compare the pharmacokinetics of Prograf and Advagraf in stable pediatric kidney transplant recipients.
- Conditions
- Kidney Transplantation, Pediatric Patients, Maintenance With Tacrolimus
- Trial name
- NCT01476488
- Testing
- tacrolimus
- Where
- South Korea
- Sponsor
- Seoul National University Hospital
Kidney Transplantation, Chronic Kidney Disease
Calcineurin Free Immunosuppression in Renal Transplant Recipients
The main purpose of this study is to obtain preliminary information on the efficacy, safety and cost of two regimens, Rapamycin / MMF / steroid therapy and Cyclosporine A Neoral / MMF / steroid therapy, used in the prevention of…
- Trial name
- NCT00812123
- Testing
- Sirolimus, Cyclosporine A, Prednisone
- Where
- Switzerland
- Volunteers
- 127 people
- Sponsor
- University Hospital, Basel, Switzerland
Rejection of Kidney Allograft
Blood Biomarkers in Pediatric Kidney Transplant Recipients
The objective of the proposed study is to assess whether a blood biomarker can be used to monitor the response to rejection treatment in pediatric kidney transplant recipients with biopsy-proven acute cellular or antibody…
- Trial name
- Omnigraf (NCT05477082)
- Testing
- Observational group
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Minnesota
Kidney Transplantation
Assessment of VZV-specific ELISPOT Assay for Predicting VZV Infection in Kidney Transplant Recipients (AVE-KT)
VZV is one of the important opportunistic infection in transplant recipients.Until now, there is no laboratory method to stratify the risk of VZV reactivation after solid organ transplantation.
- Trial name
- NCT02081729
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Asan Medical Center
Kidney Transplantation, Cytomegalovirus Infections, EBV Infection
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
Opportunistic CMV viremia (primary infection or reactivation) is usually managed by taking prophylactic medication for both adult and pediatric kidney transplant patients.
- Conditions
- Kidney Transplantation, Cytomegalovirus Infections, EBV Infection, Antiviral Prophylaxis
- Trial name
- NCT07294547
- Testing
- Valacyclovir (Valtrex), Valganciclovir (Valcyte)
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital